Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Research in context

Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Research in context

Summary: Background: The anti-Von Willebrand Factor (VWF) nanobody caplacizumab is licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in association with therapeutic plasma exchange (TPE) and immunosuppression. However, whether caplacizumab reduces mortality, and it...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Coppo, Michael Bubenheim, Ygal Benhamou, Linus Völker, Paul Brinkkötter, Lucas Kühne, Paul Knöbl, Maria Eva Mingot-Castellano, Cristina Pascual-Izquierdo, Javier de la Rubia, Julio del Rio Garma, Shruti Chaturvedi, Camila Masias, Marshall Mazepa, X. Long Zheng, György Sinkovits, Marienn Réti, Christopher J. Patriquin, Katerina Pavenski, Tiago Boechat, João Farias, Eduardo Flavio Oliveira Ribeiro, Michaela Larissa Lobo de Andrade, Agnès Veyradier, Bérangère Joly, Raïda Bouzid, Kazuya Sakai, Masanori Matsumoto, Pasquale Agosti, Ilaria Mancini, Flora Peyvandi, Eleni Gavriilaki, Matthew Stubbs, Amjad Hmaid, Spero Cataland, Bernhard Lämmle, Marie Scully
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:EClinicalMedicine
Subjects:
Thrombotic thrombocytopenic purpura
Caplacizumab
ADAMTS13
Rituximab
Prognosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025001002
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items